Curis, a publicly-traded biotechnology company (NASDAQ: CRIS), has announced it has raised $20.2 million in new funding from investors. This capital infusion is a significant development for the company, which is dedicated to the development of first-in-class and innovative therapeutics for the treatment of cancer.
The company's pipeline includes several promising drug candidates. Emavusertib (CA-4948), an orally-available IRAK4 kinase inhibitor, is currently undergoing Phase 1 clinical trials for non-Hodgkin's lymphoma, acute myeloid leukemia, and myelodysplastic syndromes. Another candidate, Fimepinostat, an orally available inhibitor of HDAC and PI3K enzymes, is being evaluated for future studies. Curis also maintains strategic collaborations, including one with Aurigene for immuno-oncology and precision oncology drug candidates, and a partnership with Roche and Genentech for the commercialization of Erivedge® (vismodegib) for advanced basal cell carcinoma.
This funding round provides Curis with additional resources to advance its critical research and development efforts. The company plans to use the proceeds to accelerate the clinical development of its pipeline programs, support ongoing preclinical studies, and strengthen its operational capabilities. Securing this investment is vital for a biotechnology firm operating in the capital-intensive drug development landscape.
The successful completion of this funding round underscores investor confidence in Curis's strategic direction and its potential to deliver meaningful advancements in cancer treatment. This financial boost is expected to support the company's mission to bring innovative therapies to patients and families affected by cancer, positioning Curis for continued growth and progress in its therapeutic development initiatives.
